US— IMS Health has acquired TTC, a Philadelphia-based benchmarking and analytics company which helps global life science organisations plan for and negotiate the costs of clinical trials.

Under the deal IMS will integrate its evidence-based, anonymised patient and treatment outcome insights with TTC’s cost data.  This is drawn from a collection of organisations that the firms claim between them conduct nearly 80% of all commercial clinical studies.

The companies say the combination will enable pharma R&D teams to improve the productivity of their clinical trials using advanced analytics and decision-support tools.

Philadelphia-based TTC offers its clients a robust set of clinical trial benchmarks, budgeting and negotiating tools to enhance the speed, efficiency and cost-effectiveness of their trial planning and management activities.  TTC maintains the world’s largest clinical grant benchmarking and negotiation database namely GrantPlan. It also serves 17 of the top 20 pharmaceutical companies and eight of the ten largest contract research companies.

Source: Research Live